Cart

0

Business

“Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply”

“Danish drugmaker Novo Nordisk’s parent company, Novo Holdings, on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection Wegovy and diabetes shot Ozempic… Novo Nordisk will then buy three of Catalent’s manufacturing… Continue Reading…

Business, Stocks

“Novo Nordisk Stock Jumps As Wegovy Sales Skyrocket 734%, Crushing Expectations”

“…For the September quarter, Novo’s sales climbed 29% to 58.73 billion Danish krone, or roughly $8.39 billion, based on today’s exchange rates. That topped the FactSet-polled analyst view for 57.88 billion Danish krone. Adjusted profit came out 5.02 Danish krone… Continue Reading…